Serascience Limited, a specialist cancer diagnostics company established by a joint venture between Abingdon Health and the University of Birmingham, announces the receipt of European CE Mark approval for the commercial sale of Seralite®, its proprietary point-of-care diagnostic device for multiple myeloma. The approval allows the Company to market the world's first point-of-care diagnostic device in multiple myeloma in the 30 countries that comprise the European Union (EU) and the European Free Trade Association (EFTA)...
No comments:
Post a Comment